Indications |
Oral Schizophrenia Adult: Initially, 5-10 mg daily adjusted in steps of 5 mg, according to response. Usual range: 5-20 mg daily. Doses >10 mg should be given only after clinical reassessment. Max: 20 mg daily. Renal impairment: Initiate at lower dose (5 mg) and increase cautiously. Hepatic impairment: Initiate at lower dose (5 mg) and increase cautiously. Oral Acute mixed or manic episodes in bipolar disorder Adult: Initially, 10 or 15 mg daily as monotherapy or 10 mg daily when used as part of combination therapy. Adjust dose in steps of 5 mg; usual range: 5-20 mg daily. For prevention of recurrence: Start with 10 mg daily. Renal impairment: Initiate at lower dose (5 mg) and increase cautiously Hepatic impairment: Initiate at lower dose (5 mg) and increase cautiously Intramuscular Rapid control of agitation and disturbed behaviour in schizophrenia or mania Adult: Initially, 5-10 mg followed by 5-10 mg as required 2 hr later. Max: 3 inj per 24-hr period; max (including oral olanzapine): 20 mg/day. May give injections for up to 3 days but should transfer to oral therapy as soon as possible. Hepatic impairment: Dose adjustments may be needed. Special Populations: Initial oral and IM dose is 5 mg daily for patients with renal and hepatic impairment. Reduce IM dose to ½ in the elderly. |
Contraindications |
Angle-closure glaucoma; lactation. IM: History of CVS disease, heart surgery. |
Warnings / Precautions |
Impaired renal, hepatic, cardiovascular function; prostatic hypertrophy; paralytic ileus; DM; parkinsonism; pregnancy. History of blood dyscrasias, myelosuppression, seizures; dementia; dyslipidaemia. IM: Hypotension, bradyarrhythmia, hypoventilation; monitor BP carefully. Caution when used in adolescents due to increased risk of weight gain and hyperlipidaemia. Efficacy and safety have not been established in paediatric patients <13 yr. |
Adverse Reactions |
Postural hypotension; constipation; dizziness; wt gain; agitation; insomnia; akathisia; tremor; personality disorders; oedema; somnolence; increased appetite; antimuscarinic effects; speech difficulty; exacerbation of Parkinson's disease; hallucinations; asthenia; increased body temperature; bradycardia; hyperprolactinaemia; QT prolongation (uncommon); asymptomatic elevations of hepatic transaminases. Potentially Fatal: Exacerbation of preexisting diabetes sometimes leading to ketoacidosis. Neuroleptic malignant syndrome. |
Overdose Reactions |
Symptoms: Tachycardia, agitation/aggressiveness, dysarthria, extrapyrimidal symptoms, sedation/coma. Induction of emesis is not recommended, gastric lavage and admin of activated charcoal may be effective. Monitor closely and treat symptomatically. |
Drug Interactions |
Olanzapine may antagonise the effects of levodopa and dopamine agonists. Drugs that induce CYP1A2 or glucuronyl transferase enzymes e.g. omeprazole and rifampicin, may increase olanzapine clearance. Inhibitors of CYP1A2 may potentially inhibit olanzapine elimination. Carbamazepine may increase the clearance of olanzapine. Concomitant admin of activated charcoal reduced the oral bioavailability of olanzapine by 50-60%. Caution should be taken when olanzapine is administered with centrally acting drugs and alcohol. See Below for More olanzapine Drug Interactions |
Mechanism of Actions |
Olanzapine is an atypical antipsychotic with affinity for serotonin 5-HT2A/2C, dopamine, muscarinic M1-M5, histamine H1 and adrenergic α1 receptors. Absorption: Well absorbed from the GI tract (oral); peak plasma concentrations after 5-8 hr (oral) or 15-45 min (IM). Distribution: Protein-binding: 93%. Metabolism: Extensively hepatic by direct glucuronidation and oxidation. Excretion: Urine (as metabolites), faeces; 30-38 hr (elimination half-life). |
Administration |
May be taken with or without food. |
Storage Conditions |
Intramuscular: Store at 15-30°C. Oral: Store at 15-30°C. |
ATC Classification |
N05AH03 - olanzapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics |
Storage |
Intramuscular: Store at 15-30°C. Oral: Store at 15-30°C. |
Available As |
|
Olanzapine
Post Review about Olanzapine Click here to cancel reply.
Olanzapine Containing Brands
Olanzapine is used in following diseases
Drug - Drug Interactions of Olanzapine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.